Invivyd Inc (IVVD)
1.84
+0.03
(+1.66%)
USD |
NASDAQ |
May 31, 16:00
1.83
-0.01
(-0.54%)
After-Hours: 20:00
Invivyd Cash from Financing (TTM): 39.60M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 39.60M |
December 31, 2023 | 1.045M |
September 30, 2023 | 1.045M |
June 30, 2023 | 1.199M |
March 31, 2023 | 1.003M |
Date | Value |
---|---|
December 31, 2022 | 0.506M |
September 30, 2022 | -0.384M |
June 30, 2022 | 327.97M |
March 31, 2022 | 662.73M |
December 31, 2021 | 662.68M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-0.384M
Minimum
Sep 2022
662.73M
Maximum
Mar 2022
169.74M
Average
1.122M
Median
Cash from Financing (TTM) Benchmarks
Vanda Pharmaceuticals Inc | -- |
Viking Therapeutics Inc | 873.23M |
Stoke Therapeutics Inc | 9.67M |
180 Life Sciences Corp | 6.113M |
MAIA Biotechnology Inc | 13.99M |